BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Klifovet’s client base comprises the world’s top animal health and nutrition companies as well as many promising startups
The order strengthens the company’s position in the East African market
The net proceeds from the issue will be utilised towards the purchase of machinery, modernising existing units and expansion of its R&D facilities
The division will focus on products that are required during ophthalmic surgical procedures like cataracts and refractive surgeries among others
This low-cost and highly reliable technology will help in increasing testing in rural and tribal areas
HTL will build, validate and operate a botulinum manufacturing facility in the US
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
Over 70 per cent of the world’s population have no access to MRI scanners and the situation is not that encouraging in India where there are only 0.4 MRI scanners per thousand people
Subscribe To Our Newsletter & Stay Updated
